SHARE
 
Glenn Liu, MD close
EW7oV-dVusU
Glenn Liu, MD
 

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Glenn Liu, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Liu joined the faculty as an Assistant Professor of Medicine at the University of Wisconsin in 2003, where he currently specializes in genitourinary oncology and experimental therapeutics. Previously, Dr. Liu did his undergraduate training at Dartmouth College, where he majored in biochemical engineering. From there, he received his Master's Degree at Boston University before obtaining his MD at Jefferson Medical College. Dr. Liu completed his internal medicine and oncology training at the University of Wisconsin Hospital and Clinics, with additional training in genitourinary oncology as part of a K12 grant at the University of Wisconsin Carbone Cancer Center.

Specialties

Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 263-4757 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship Oncology, University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Thomas Jefferson Medical College, Philadelphia, PA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Liu specializes in the treatment of all genitourinary cancers and is a recognized clinical researcher as evident by his service on the Eastern Cooperative Oncology Group (ECOG) Genitourinary Oncology Core Committee as the Genitourinary (GU) Liaison for the ECOG Developmental Therapeutics Committee, for which he is also a member. He currently serves as the disease group leader for the GU Oncology Disease Group, a NCI-designated Phase II Consortium, and thus is highly active in local, regional, and national trials in all stages of development. Dr. Liu is also a member of the experimental therapeutics (Phase I) program at the UW Carbone Cancer Center, and thus is involved in early drug development.


PubMed Articles
Roth AR Harmon SA Perk TG Eickhoff J Choyke PL Kurdziel KA Dahut WL Apolo AB Morris MJ Perlman SB Liu G Jeraj R Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer . 2019 Aug;17(4):306-314
[PubMed ID: 31221545]
Heath E Heilbrun L Mannuel H Liu G Lara P Monk JP Flaig T Zurita A Mack P Vaishampayan U Stella P Smith D Bolton S Hussain A Al-Janadi A Silbiger D Usman M Ivy SP Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist . 2019 May 31;
[PubMed ID: 31152080]
Weisman AJ Harmon SA Perk TG Eickhoff J Choyke PL Kurdziel KA Dahut WL Humm JL Apolo AB Larson SM Morris MJ Perlman SB Liu G Jeraj R Quantification of bone flare on <sup>18</sup>F-NaF PET/CT in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis . 2019 May;22(2):324-330
[PubMed ID: 30413807]
Scarpelli M Zahm C Perlman S McNeel DG Jeraj R Liu G FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer . 2019 Jan 30;7(1):23
[PubMed ID: 30700328]
Lin C Harmon S Bradshaw T Eickhoff J Perlman S Liu G Jeraj R Response-to-repeatability of quantitative imaging features for longitudinal response assessment. Phys Med Biol . 2019 Jan 18;64(2):025019
[PubMed ID: 30566922]
Perk T Bradshaw T Chen S Im HJ Cho S Perlman S Liu G Jeraj R Automated classification of benign and malignant lesions in <sup>18</sup>F-NaF PET/CT images using machine learning. Phys Med Biol . 2018 Nov 20;63(22):225019
[PubMed ID: 30457118]
Perk T Chen S Harmon S Lin C Bradshaw T Perlman S Liu G Jeraj R A statistically optimized regional thresholding method (SORT) for bone lesion detection in <sup>18</sup>F-NaF PET/CT imaging. Phys Med Biol . 2018 Nov 20;63(22):225018
[PubMed ID: 30457117]
Kolesar JM Liu G Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. J Clin Oncol . 2018 Oct 20;36(30):3065-3066
[PubMed ID: 30188791]
Monk P Liu G Stadler WM Geyer S Huang Y Wright J Villalona-Calero M Wade J Szmulewitz R Gupta S Mortazavi A Dreicer R Pili R Dawson N George S Garcia JA Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs . 2018 Oct;36(5):919-926
[PubMed ID: 30083962]
Bekelman JE Rumble RB Chen RC Pisansky TM Finelli A Feifer A Nguyen PL Loblaw DA Tagawa ST Gillessen S Morgan TM Liu G Vapiwala N Haluschak JJ Stephenson A Touijer K Kungel T Freedland SJ Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol . 2018 Sep 5;:JCO1800606
[PubMed ID: 30183466]
Scarpelli M Rampurwala M Eickhoff J Carmichael L Heideman J Binger K Kolesar J Perlman S Harrow K Dukart G Liang C Jeraj R Liu G Bruce JY Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemother Pharmacol . 2018 Aug;82(2):211-219
[PubMed ID: 29802443]
Scarpelli M Simoncic U Perlman S Liu G Jeraj R Dynamic <sup>18</sup>F-FLT PET imaging of spatiotemporal changes in tumor cell proliferation and vasculature reveals the mechanistic actions of anti-angiogenic therapy. Phys Med Biol . 2018 Jul 27;63(15):155008
[PubMed ID: 29978839]
Engle JA Traynor AM Campbell TC Wisinski KB LoConte N Liu G Wilding G Kolesar JM Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract . 2018 Jul;24(5):348-353
[PubMed ID: 28457192]
Gravis G Boher JM Chen YH Liu G Fizazi K Carducci MA Oudard S Joly F Jarrard DM Soulie M Eisenberger MJ Habibian M Dreicer R Garcia JA Hussain MHM Kohli M Vogelzang NJ Picus J DiPaola R Sweeney C Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol . 2018 Jun;73(6):847-855
[PubMed ID: 29475737]
McNeel DG Eickhoff JC Wargowski E Zahm C Staab MJ Straus J Liu G Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget . 2018 May 22;9(39):25586-25596
[PubMed ID: 29876010]
Kolesar JM Liu GX Low-Fat Abiraterone Food Effect Is of Little Consequence. J Clin Oncol . 2018 May 10;36(14):1385-1386
[PubMed ID: 29590006]
Kyriakopoulos CE Chen YH Carducci MA Liu G Jarrard DF Hahn NM Shevrin DH Dreicer R Hussain M Eisenberger M Kohli M Plimack ER Vogelzang NJ Picus J Cooney MM Garcia JA DiPaola RS Sweeney CJ Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol . 2018 Apr 10;36(11):1080-1087
[PubMed ID: 29384722]
Wargowski E Johnson LE Eickhoff JC Delmastro L Staab MJ Liu G McNeel DG Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer . 2018 Mar 13;6(1):21
[PubMed ID: 29534736]
Harshman LC Chen YH Liu G Carducci MA Jarrard D Dreicer R Hahn N Garcia JA Hussain M Shevrin D Eisenberger M Kohli M Plimack ER Cooney M Vogelzang NJ Picus J Dipaola R Sweeney CJ ECOG-ACRIN 3805 Investigators. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol . 2018 Feb 1;36(4):376-382
[PubMed ID: 29261442]
Pili R Jegede O Carducci MA Manola J Groteluschen DL Appleman LL Liu G Shanks JC Dakhil SR Dutcher J DiPaola RS A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clin Genitourin Cancer . 2017 Dec;15(6):642-651.e1
[PubMed ID: 28545998]